Novartis Ag (NVS) Depreciation & Amortization (CF) (2009 - 2018)

Novartis Ag (NVS) posted Depreciation & Amortization (CF) of $930.0 million for Q1 2018, up 139849524.06% sequentially from $665.0 in Q2 2010.

Novartis Ag (NVS) Depreciation & Amortization (CF) (2009 - 2018) Analysis & Trends

Novartis Ag (NVS) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $930.0 million in Q1 2018.

Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $930.0 million in Q1 2018, while the trailing twelve-month figure through Dec 2018 was $930.0 million (changed N/A YoY) and the FY2009 annual result came in at $2341.0, changed N/A from the prior year.
Depreciation & Amortization (CF) climbed to $930.0 million in Q1 2018 per NVS's latest filing, from $665.0 in the prior quarter.
The five-year high for Depreciation & Amortization (CF) was $930.0 million in Q1 2018, with the low at $930.0 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Dep. & Amort. (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	509.00 Mn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	2.00 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	188.00 Mn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	1.37 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	581.00 Mn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	1.12 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	93.00 Mn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	1.61 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn	204.40 Mn

Download Data